Top Story

Lenvatinib, sorafenib may significantly impact treatment of differentiated thyroid cancer

November 13, 2014

Marcia S. Brose, MD, PhD, associate professor at the University of Pennsylvania and director of the thyroid cancer therapeutics program and of the Centers of Rare Cancer Research, discusses how clinicians identify patients with differentiated thyroid cancer who are well-suited for aggressive or less aggressive treatment regimens.

Brose notes that with emerging active agents such as sorafenib (Nexavar; Bayer Health Care, Onyx) and lenvatinib (E7080, Eisai), researchers must identify subgroups of patients who are likely to have the most benefit with the least toxicity from each therapy.

In the Journals

BRAF V600E mutation increased recurrence risk in papillary thyroid cancer

November 12, 2014
Presence of a BRAF V600E mutation appeared to predict recurrence in patients treated for papillary thyroid cancer, according to results of a retrospective, multicenter…
thumbnail for video 3886443649001 Meeting News CoverageVideo

Risk stratification guidelines help determine treatment for thyroid cancer

November 11, 2014
Fabian Pitoia, MD,  head of the thyroid section of the division of endocrinology at the Hospital de Clinicas of the University of Buenos Aires, discusses how risk…
In the Journals

Thyroid cancer conditional survival affected by age, cancer stage, survivorship phase

November 11, 2014
In patients with thyroid cancer, conditional survival appears to be affected by cancer stage, age at diagnosis and duration of survival to date from diagnosis, according…
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
thumbnail for video 3886443649001

Risk stratification guidelines help determine treatment for thyroid cancer

November 11, 2014
Fabian Pitoia, MD,  head of the thyroid section of the division of endocrinology at the Hospital de Clinicas of…
More »
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
thumbnail for video 3890508474001 Meeting News CoverageVideo

Lenvatinib, sorafenib may significantly impact treatment of differentiated thyroid cancer

November 13, 2014
Marcia S. Brose, MD, PhD, associate professor at the University of Pennsylvania and director of the thyroid cancer therapeutics program and of the…
In the Journals

BRAF V600E mutation increased recurrence risk in papillary thyroid cancer

November 12, 2014
Presence of a BRAF V600E mutation appeared to predict recurrence in patients treated for papillary thyroid cancer, according to results of a…
thumbnail for video 3886443649001 Meeting News CoverageVideo

Risk stratification guidelines help determine treatment for thyroid cancer

November 11, 2014
Fabian Pitoia, MD,  head of the thyroid section of the division of endocrinology at the Hospital de Clinicas of the University of Buenos Aires…
In the Journals

Thyroid cancer conditional survival affected by age, cancer stage, survivorship phase

November 11, 2014
In patients with thyroid cancer, conditional survival appears to be affected by cancer stage, age at diagnosis and duration of survival to date from…
In the Journals

Chronic dental trauma potential oral cavity cancer carcinogen

November 6, 2014
Patients with oral cavity cancers who were nonsmokers were more likely than smokers to have tumors in sites associated with chronic dental trauma…
In the Journals

p16 expression predicted outcomes in non-OPSCC

November 3, 2014
Patients with p16-positive non-oropharyngeal squamous cell carcinoma experienced better outcomes than those with p16-negative tumors, according to an…
Meeting News Coverage

Postoperative symptomatic hypocalcemia linked to preoperative vitamin D deficiency in thyroid cancer

November 2, 2014
CORONADO, Calif. — Patients with thyroid cancer who also have preoperative vitamin D deficiency are at increased risk of postoperative…
Ian Ganly Meeting News Coverage

Nomogram predicts prognosis, guides follow-up plans in patients with medullary thyroid cancer

November 1, 2014
CORONADO, Calif. — A predictive nomogram can help assist in counseling of patients with medullary thyroid cancer in terms of prognosis as well…
Meeting News Coverage

Survival benefit found with RAI, all sizes of papillary thyroid carcinoma tumors

November 1, 2014
CORONADO, Calif. — Survival benefit was found with use of RAI for all sizes of papillary thyroid carcinoma tumors, according to study findings…
Meeting News Coverage

BRAF mutation linked to recurrence in differentiated thyroid cancer

October 31, 2014
CORONADO, Calif. — The incidence of the BRAF V600E mutation, in the absence of other somatic mutations, was significantly associated with…
More Headlines »
morganatic-roan
morganatic-roan